Literature DB >> 23075707

Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Carol A Paronis1, Spyros P Nikas, Vidyanand G Shukla, Alexandros Makriyannis.   

Abstract

Δ-Tetrahydrocannabinol (THC) has been characterized as a partial agonist at cannabinoid CB1 receptors in vitro; however, it often produces the same maximum effects in vivo as other cannabinoid agonists. This study was carried out to determine whether THC would antagonize the hypothermic effects of another cannabinoid agonist, AM2389, in mice. Male mice were injected with 1-100 mg/kg THC, 0.01-0.1 mg/kg AM2389, or a combination of 30 mg/kg THC and 0.1-1.0 mg/kg AM2389, and rectal temperature was recorded for up to 12 h after injection. THC reduced the temperature by 5.6°C at a dose of 30 mg/kg; further increases in the dose did not produce larger effects, indicating a plateau in the THC dose-effect function. AM2389 reduced temperature by 9.0°C at a dose of 0.1 mg/kg. One hour pretreatment with 30 mg/kg THC attenuated the hypothermic effects of 0.1 mg/kg AM2389; a 10-fold higher dose, 1.0 mg/kg AM2389, was required to further decrease temperature, reflecting a five-fold rightward shift of the lower portion of the AM2389 dose-effect function following THC pretreatment. These results indicate that, in an assay of mouse hypothermia, THC exerts both agonist and antagonist effects following acute administration, and mark the first demonstration of partial agonist/antagonist effects of THC in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075707      PMCID: PMC3697741          DOI: 10.1097/FBP.0b013e32835a7c4d

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  22 in total

1.  Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.

Authors:  C S Breivogel; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.

Authors:  J U Adams; C A Paronis; S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

3.  Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.

Authors:  L J Sim; R E Hampson; S A Deadwyler; S R Childers
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

4.  Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.

Authors:  C A Paronis; S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1992-07       Impact factor: 4.030

5.  Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.

Authors:  Sophie J Govaerts; Emmanuel Hermans; Didier M Lambert
Journal:  Eur J Pharm Sci       Date:  2004-11       Impact factor: 4.384

6.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

Authors:  D R Compton; L H Gold; S J Ward; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

7.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

Authors:  F Fan; D R Compton; S Ward; L Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

8.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

9.  Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.

Authors:  E A Walker; G Zernig; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  36 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

2.  Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Authors:  Carol A Paronis; Girish R Chopda; Kiran Vemuri; Ani S Zakarian; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2018-01-08       Impact factor: 4.030

3.  Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Aneetha Halikhedkar; JodiAnne Wood; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

Review 4.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

5.  Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors.

Authors:  Xiao-Fei Wang; Ewa Galaj; Guo-Hua Bi; Cindy Zhang; Yi He; Jia Zhan; Michael H Bauman; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

Review 6.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 7.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

8.  Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats.

Authors:  Krista J Spiller; Guo-Hua Bi; Yi He; Ewa Galaj; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2019-04-03       Impact factor: 8.739

9.  Controlled-deactivation cannabinergic ligands.

Authors:  Rishi Sharma; Spyros P Nikas; Carol A Paronis; Jodianne T Wood; Aneetha Halikhedkar; Jason Jianxin Guo; Ganesh A Thakur; Shashank Kulkarni; Othman Benchama; Jimit Girish Raghav; Roger S Gifford; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-12-10       Impact factor: 7.446

10.  Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.

Authors:  Giuseppe Tortoriello; Claudia V Morris; Alan Alpar; Janos Fuzik; Sally L Shirran; Daniela Calvigioni; Erik Keimpema; Catherine H Botting; Kirstin Reinecke; Thomas Herdegen; Michael Courtney; Yasmin L Hurd; Tibor Harkany
Journal:  EMBO J       Date:  2014-01-27       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.